Stocksigma LogoStocksigma Logo

Windlas Biotech Delivers Robust H1FY27 Performance with Strong CDMO Growth

Windlas Biotech reported Q2FY27 revenue of Rs. 264 Cr (+19% YoY) and H1FY27 revenue of Rs. 512 Cr (+18% YoY), driven by Generic Formulations CDMO surging

Windlas Biotech Delivers Robust H1FY27 Performance with Strong CDMO Growth

Windlas Biotech Ltd 路 Investor Presentation 路 05 Nov 2026, 10:31 pm

Windlas Biotech Delivers Robust H1FY27 Performance with Strong CDMO Growth Windlas Biotech reported Q2FY27 revenue of Rs. 264 Cr (+19% YoY) and H1FY27 revenue of Rs. 512 Cr (+18% YoY), driven by Generic Formulations CDMO surging 32% YoY to Rs. 422 Cr in H1FY27 (82% mix). H1FY27 adjusted EBITDA grew 23% YoY to Rs. 70 Cr (13.7% margin) and adjusted PAT rose 33% YoY to Rs. 50 Cr. Plant-6 was commercialized in Sep'26, while Plant-4 and Plant-5 received EU-GMP certifications. The company remains net-debt-free with Rs. 223 Cr net liquidity, delivering an H1FY27 annualized ROCE of 38%.

Original exchange filing (PDF)

More announcements from Windlas Biotech Ltd

All Windlas Biotech Ltd announcements